Join        Login             Stock Quote

Agere Executives to Discuss Enhancing Oral Bioavailability Using Amorphous Molecular Dispersions at ExL Pharma's "Enhancing Drug Bioavailability and Solubility" Conference

Thursday, January 10, 2013 7:05 AM

Agere Pharmaceuticals, Inc., a leading oral bioavailability contract research and manufacturing organization (CRO/CMO), will present, facilitate and participate in a panel discussion at ExL Pharma’s 2nd annual conference focused on solubility and bioavailability in Boston, January 21 – 23, 2013. www.exlpharma.com/bioavailability


      Presentation: “Enhancing Oral Bioavailability using Amorphous Molecular Dispersions: Industry Implications and Approaches for Successful cGMP Formulation Development”
-- Formulation paradigm shift in the industry
-- Screening Polymers & Drug Loading: Performance and Stability
-- Small Scale Approaches to amorphous Dispersion formulations
-- Scale-up and cGMP Manufacturing of Solid Dispersion Formulation


Marshall Crew, CEO and Founder, Agere Pharmaceuticals, Inc.


Wednesday, January 23, at 3:20 p.m.




Panel Discussion: “Advancing Amorphous Molecular Dispersions Through the Clinic: Practical Aspects of cGMP Manufacturing”
-- Product control strategies and risk management for clinical phase products
-- Dosage form options, excipient selections and decision making for first in human studies
-- Design development and scale up approaches for successful cGMP manufacturing
-- Analytical testing and regulatory considerations specific to amorphous molecular dispersions


Marshall Crew, CEO and Founder, Agere (Moderator)
Vince Foley, Director of Quality, Agere
Ryan Minikis, Senior Director Formulation and Chemistry, Agere
Ravi Shanker, Senior Research Investigator, Pfizer, Inc.


Tuesday, January 22, at 10 a.m.

All sessions of the conference will be held at the Omni Parker House Hotel, Boston, MA.

For more information, and to obtain a special conference discount Agere is extending to clients, please contact Agere at 541-639-8397 or www.agerepharma.com.

About Agere

Agere is a leading CRO/CMO focused on improving the oral bioavailability of insoluble APIs. The company supports clients from formulation design and development through cGMP manufacturing for Phase I, Phase IIa and Phase IIb clinical trials. Agere is expert in solid dispersion techniques including spray drying and hot melt extrusion (HME), and in a broad selection of solid dosage forms. All services are delivered on a fee-for-service basis, and every project the company undertakes is customized to serve each individual client’s requirements. Agere is located in Bend, OR. For information: www.agerepharma.com.

(Source: Business Wire )
(Source: Quotemedia)


Related Stories

  • No Stories Found


Fundamental data is provided by Zacks Investment Research, and Commentary, news and Press Releases provided by YellowBrix and Quotemedia.
All information provided "as is" for informational purposes only, not intended for trading purposes or advice. iStockAnalyst.com is not an investment adviser and does not provide, endorse or review any information or data contained herein.
The blog articles are opinions by respective blogger. By using this site you are agreeing to terms and conditions posted on respective bloggers' website.
The postings/comments on the site may or may not be from reliable sources. Neither iStockAnalyst nor any of its independent providers is liable for any informational errors, incompleteness, or delays, or for any actions taken in reliance on information contained herein. You are solely responsible for the investment decisions made by you and the consequences resulting therefrom. By accessing the iStockAnalyst.com site, you agree not to redistribute the information found therein.
The sector scan is based on 15-30 minutes delayed data. The Pattern scan is based on EOD data.